Saltar al contenido
Merck

A case of extreme prematurity and delayed diagnosis of pyridoxine-dependent epilepsy.

Neurosciences (Riyadh, Saudi Arabia) (2012-10-02)
Abdulaziz S Al-Saman, Tamer M Rizk
RESUMEN

Pyridoxine-dependent epilepsy presents early in life, even in utero. It is usually refractory to conventional antiepileptic medications and responds only to lifelong pyridoxine supplementation. Seizures are usually generalized tonic clonic. We report a 3-year-old child that was born prematurely at 25 weeks of gestation. He presented with abnormal movements in the second month of life. At 10 months of age he presented with status epilepticus, which was refractory to multiple antiepileptic medications and was controlled with intravenous pyridoxine. An elevated level of a-aminoadipic semialdehyde excretion in the urine supported the diagnosis of pyridoxine-dependent epilepsy. Subsequently, a c.1195G>C homozygous mutation in the 5q31 aldehyde dehydrogenase 7A1 gene was confirmed. This case calls for considering pyridoxine-dependent epilepsy and its early management in cases with resistant seizures; even in the presence of extreme prematurity with its neurological consequences.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Pyridoxine hydrochloride, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture
Supelco
Pyridoxine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Pyridoxine, ≥98%
Supelco
Pyridoxine Hydrochloride (B6), analytical standard
Sigma-Aldrich
Pyridoxine hydrochloride, ≥98% (HPLC)
Sigma-Aldrich
DL-2-Aminoadipic acid, ≥99%
Sigma-Aldrich
Pyridoxine hydrochloride, meets USP testing specifications
Pyridoxine hydrochloride, European Pharmacopoeia (EP) Reference Standard